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Glioblastoma multiforme is the most aggressive primary tumor of the central nervous system. Glioma stem cells (GSCs), a
small population of tumor cells with stem-like properties, are supposedly responsible for glioblastoma multiforme relapse
after current therapies. In approximately thirty percent of glioblastoma multiforme tumors, telomeres are not maintained by
telomerase but through an alternative mechanism, termed alternative lengthening of telomere (ALT), suggesting potential
interest in developing specific therapeutic strategies. However, no preclinical model of ALT glioma was available until the iso-
lation of TG20 cells from a human ALT glioma. Herein, we show that TG20 cells exhibit a high level of telomeric recombination
but a stable karyotype, indicating that their telomeres retain their protective function against chromosomal instability. TG20
cells possess all of the characteristic features of GSCs: the expression of neural stem cell markers, the generation of intrace-
rebral tumors in NOD-SCID-IL2Rc (NSG) mice as well as in nude mice, and the ability to sustain serial intracerebral transplan-
tations without expressing telomerase, demonstrating the stability of the ALT phenotype in vivo. Furthermore, we also
demonstrate that 360B, a G-quadruplex ligand of the pyridine derivative series that impairs telomere replication and mitotic
progression in cancer cells, prevents the development of TG20 tumors. Together, our results show that intracerebral grafts of
TG20 cells in immunodeficient mice constitute an efficient preclinical model of ALT glioblastoma multiforme and that
G-quadruplex ligands are a potential therapy for this specific type of tumor.
Key words: glioma stem cells, telomerase, alternative lengthening of telomeres, in vivo model, G-quadruplex ligands
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Telomerase is activated in most tumor cells to maintain telo-
mere length, which is required for long-term proliferative
capability.1 However, tumors lacking telomerase can rely on a
different mechanism for telomere elongation, referred to as
alternative lengthening of telomeres (ALT).2 While several
studies have shown that ALT depends on homologous recom-
bination between telomeres,3 it is not yet clear how the ALT
machinery is activated and what mechanisms are involved.
The ALT pathway is predominant in osteosarcoma4 and is
detected in approximately 30% of glioblastoma multiforme,5
the most common and malignant primary tumor of the adult
central nervous system. While several ALT cell lines have been
derived from osteosarcoma patients, we were the ﬁrst to
describe an ALT glioma cell line, TG20, which was obtained
from an ALT glioma patient.6 We have shown that TG20 cells
display markers and characteristics of ALT cells, such as the
lack of telomerase expression, the presence of ALT-associated
PML bodies, and heterogeneous telomere length.6 A second
ALT glioma cell line has recently been reported.7
Gliomas have been shown to contain a small population
of cancer cells, termed glioma stem cells (GSCs), which share
some properties with neural stem cells. These cells are more
resistant to current treatments than the other “differentiated”
cancer cells and are able to regenerate the tumor because of
their stem properties.8 Understanding the biology of GSCs is
thus crucial for developing speciﬁc therapies to prevent
tumor relapse. We have shown that TG20 cells exhibit the
phenotype and properties of GSCs, such as the expression of
neural stem cell markers, the capacity for long-term prolifera-
tion in vitro, and the ability to form intracranial tumors in
immunodeﬁcient mice.6
All cancerous cells share the need to maintain and elon-
gate their telomeres. Therefore, telomeres and their mainte-
nance machinery constitute an appealing target for anticancer
therapies. Various strategies for telomerase inhibition have
been emerging based on chemical inhibitors, antisense oligo-
nucleotides, and immunotherapies.9 However, telomerase
inhibition is inadequate for tumors lacking telomerase and is
potentially capable of activating ALT as a mechanism of drug
resistance.10 A more common putative target for telomere-
targeting therapies could be G-quadruplexes, which are sec-
ondary structures commonly formed by telomeres.11 Several
G-quadruplex ligands (e.g., BRCAO19, RHPS4, telomestatin
and 360A) have been designed and have shown efﬁciency in
reducing cancer cell proliferation and/or tumor growth,12–17
but limited data are available regarding the effects of G-
quadruplex ligands on ALT cells.
In the present work, we further characterized the ALT
phenotype and the GSC properties of TG20 cells. We showed
that intracerebral grafts of TG20 cells represent an efﬁcient
preclinical model of ALT glioma that helps reveal the sensi-
tivity of these cells to the G-quadruplex ligand 360B, a more
soluble derivative of 360A, known to impair telomere replica-
tion and mitotic progression in cancer cells.17–19
Materials and Methods
Cell culture
Telomerase-positive GSCs, including the TG16, TG1N, TG10
and OB1 cell lines, and the ALT GSC TG20 line were derived
from tumor samples obtained from patients at Sainte Anne
Hospital (Paris, France). This procedure was approved by the
Institutional Review Board and patients provided an
informed consent. GSCs were grown in neurospheres in
serum-free Dulbecco’s modiﬁed eagle medium (DMEM)/F12
supplemented with B27 (Gibco, Life Technologies), heparin
(Stem Cell Technologies), human recombinant epidermal
growth factor (EGF), and basic ﬁbroblast growth factor
(FGF2; Sigma), as previously described.6,20 eGFP-positive
TG20 cells were obtained through lentiviral transfection, as
previously described.6 The osteosarcoma ALT cell line SAOS-
2 was grown in DMEM (Gibco, Life Technologies) supple-
mented with 10% fetal bovine serum (PAA Laboratories).
5-Azacytidine treatment
GSCs were grown as adherent cultures on laminin (Milli-
pore)-coated ﬂasks. Medium was supplemented with DMSO
or with 2.5 or 5 lM 5-azacytidine (A2385; Sigma). Cells were
treated three times every 24 hr. At 48 hr after the last treat-
ment, the cells were collected as dry pellets.
WST-1 cell proliferation assay
A total of 5,000 TG20 cells were plated in 96-well plates that
were previously coated with laminin (Millipore) to allow cell
adherence. The WST-1 assay (11644807001; Roche) was then
performed at different time points according to the manufac-
turer’s instructions.
Telomeric sister chromatid exchange
Chromosome orientation FISH (CO-FISH) was performed as
previously described.21 Brieﬂy, cells were grown as adherent
What’s new?
All cancerous cells share the need to maintain and elongate their telomeres. In approximately 30% of glioblastoma multiforme
tumors, telomeres are not maintained by telomerase but through an alternative mechanism, termed ALT, making specific ther-
apeutic strategies potentially interesting. Here, the authors showed that intracerebral grafts of an ALT glioma cell line called
TG20 in immunodeficient mice constitute an efficient preclinical model of ALT glioblastoma multiforme, which could aid the
understanding of the underlying pathogenesis. This model could also support the development of specific therapies, with the
study revealing G-quadruplex ligands as a potential therapy for this specific type of tumor.
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cultures in culture medium supplemented with 10 lM BrdU
for one cell cycle. Metaphase spreads were stained with
Hoechst 33258, exposed to ultraviolet (UV) light, and
digested with exonuclease III (Promega). Successive hybrid-
izations with a FITC-labeled (TTAGGG)3 PNA probe
(Applied Biosystems) and a Cy-3-labeled (CCCTAA)3 PNA
probe allowed the detection of the parental telomere C and
G strands. Metaphase images were captured and analyzed
using an Axio Imager Z.2 (Zeiss, Germany) coupled to a
Metafer Image Analysis System (MetaSystems, Germany).
Sister chromatid exchange
Cells were cultured in medium supplemented with 10 mM BrdU
for two cell cycles. After the addition of 10 mg/mL colchicine for 2
h, cells were collected and incubated in KCl (0.075 M) and
human serum (1:6 v/v) for 20 min at 37C, ﬁxed in ethanol/acetic
acid (3:1 v/v), and spread onto cold, clean slides. The slides were
incubated in 50 mg/mL Hoechst (33258) dye for 20 min and then
denatured by exposure to UV light at 365 nm (Fisher Bioblock
Scientiﬁc) for 30min in the presence of 23 SSC. After washing in
double-distilled water, the slides were stained with 1.5% Giemsa
and 1.5% phosphate buffer in double-distilled water. Metaphases
were observed under a microscope (Olympus AX70) and ana-
lyzed using the Cytovision system. The sister chromatid exchange
(SCE) frequency was calculated as the total number of SCEs
divided by the total number of chromosomes.
Multi-FISH analysis
Metaphase spreads were prepared as for CO-FISH experiments.
Metaphases were hybridized with a 24 XCyte probe kit (Meta-
Systems, Altlussheim, Germany) according to the manufac-
turer’s instructions. Images were captured and analyzed using
an Axioplan ﬂuorescence microscope (Zeiss, Germany) with the
appropriate ﬁlters and M-FISH software (ISIS, MetaSystems).
2D gel electrophoresis and genomic blotting
DNA was phenol-chloroform extracted, ethanol precipitated,
resuspended in nuclease-free water, and digested with MboI
(New England Biolabs) for 4 hr at 37C. For the ﬁrst dimen-
sion, 25 mg of total DNA was subjected to electrophoresis in
a 0.4% agarose gel at 1 V/cm for 18 hr at RT. The lanes were
excised, and a 1% agarose gel in 13 TBE containing ethi-
dium bromide was poured around the excised slab. The sec-
ond dimension of electrophoresis was performed at 5 V/cm
for 3 hr. Gels were treated with 5 M NaOH and 1 M NaCl
for 20 min to denature the DNA, transferred overnight onto
nitrocellulose membranes (Whatman), and UV cross-linked.
Hybridization with a telomeric C-rich digoxigenin probe was
performed in Church’s buffer at 42C for 12 hr. Telomeric
DNA was visualized with Digoxigenin DNA Detection Kits
(Roche) using an LAS-4000 camera (Fuji).
Quantitative real-time polymerase chain reaction
Total RNA was extracted using the RNeasy Plus Mini kit
(Qiagen) according to the manufacturer’s instructions.
Isolated RNA was transcribed to cDNA using the High-
Capacity RNA-to-cDNA Master Mix (Applied Biosystems).
Quantitative real-time polymerase chain reactions (RT-PCRs)
were performed in 96-well plates in duplicate using SYBR
Green Master Mix (Applied Biosystems). The primers used
are listed in Supporting Information Table S1.
Methylation-specific PCR
Cellular genomic DNA was isolated as previously described.22
Bisulﬁte modiﬁcation and DNA puriﬁcation were performed
using the EZ DNA methylation kit (Zymo Research, Protei-
gene, Saint-Marcel, France) following the manufacturer’s
instructions. Primers speciﬁc for the unmethylated and meth-
ylated alleles of hTERT were used to amplify bisulﬁte-
modiﬁed DNA as previously described.23 Methylation-speciﬁc
PCR (MSP) primers were designed for a proximal region
encompassing the transcription and translation start sites and
the WT1 consensus binding site. The primer sequences and
conditions are presented in Supporting Information Table S2.
PCR was performed on bisulﬁte-treated DNA using Zymo-
TaqTM DNA Polymerase (Zymo Research, Proteigene, Saint-
Marcel, France). PCR products were separated on 2% agarose
gels and visualized after ethidium bromide staining.
Telomerase activity assay
Telomerase activity was measured after neurosphere growth,
using the TRAPeze ELISA Telomerase Detection Kit (Chemi-
con) according to the manufacturer’s instructions. Proteins
were extracted using the lysis buffer (CHAPS) provided in
the kit, and 0.5 or 1 lg of protein extract was used.
Western blot
Cells were collected as dry pellets and then lysed using RIPA
buffer (R0278; Sigma) supplemented with protease
(11873580001; Roche) and phosphatase inhibitors (78420;
Thermo Scientiﬁc). Thirty micrograms of protein was diluted
in RIPA buffer supplemented with LDS Sample Buffer
(NP0007; Invitrogen by Life technologies) and Sample Reduc-
ing Agent (NP004; Novex by Life Technologies). Samples
were heated for 5 min at 95C and loaded into NuPAGE 4–
12% Bis-Tris gels (NP0322BOX; Novex by Life Technolo-
gies). For electrophoresis, NuPAGE running buffer (NP001;
Novex by Life Technologies) was used. Protein transfer was
performed using nitrocellulose membranes (LC2000; Invitro-
gen by Life Technologies) and NuPAGE Transfer Buffer
(NP0006-1; Invitrogen by Life Technologies). WT1 (Wilm’s
tumor protein 1) antibody (1:400, NB-110–60011; Novus Bio-
logicals) was used to detect the WT1 protein.
Mice
Three-month-old male NOD-SCID-IL2Rg (NSG) mice (25–
30 g) and 3-month-old nude mice (Swissnu/nu; 25–30 g) from
Charles River Laboratories (L’Arbresle, France) were used in
this study. Animals were provided with food and water ad
libitum and housed in a colony isolator maintained at a
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constant temperature of 19–22C and humidity (40–50%) on
a 12:12 hr light/dark cycle. The experiments were performed
in compliance with the European Communities Council
Directive of November 24, 1986 (86/609/EEC) and the prin-
ciples of laboratory animal care (NIH publication No. 85-23,
revised 1985) and were approved by our institutional com-
mittee on animal welfare (CETEA-CEA DSV IdF, saisine
number #12–029). All surgical procedures were performed
under anesthesia with ketamine (75 mg/kg, Imalgen; Merial,
Lyon, France) and medetomidine (1 mg/kg, Domitor; Pﬁzer,
Paris, France). After the surgery, paracetamol (1.64 mg/mL,
Doliprane; Sanoﬁ, France) was administered in the drinking
water for 1 week.
Serial intracranial transplantations
70,000–100,000 TG20-eGFP GSCs were injected stereotaxi-
cally into the striatum of 3-month-old NSG mice, as previ-
ously described.6 After 2 or 3 months, mice were sacriﬁced
by cervical dislocation, and brain tissues containing eGFP-
positive cells were micro-dissected using a Carl-Zeiss Lumar
ﬂuorescence stereomicroscope. The dissected tissues were
pelleted and dissociated in 0.5% trypsin (Gibco, Life
Technologies) and 0.5 mg/mL DNase I (Roche) for 15 min at
37C. eGFP-positive cells were sorted by FACS (INFLUX cell
sorter, BD), and dead cells were excluded by propidium
iodide incorporation (10 mg/mL). Sorted cells were resus-
pended in PBS (0.15% BSA) and reinjected (100,000 cells in
2 mL) into 3-month-old NSG mice.
G-quadruplex (G4) ligand (360B) treatment
360B is a close derivative of the previously described G-
quadruplex ligand 360A. 360B was prepared in two steps
from 2,6-pyridine-dicarboxylic acid and uinolone-3-amine, in
an overall 72% yield after recrystallization from ethanol. 1H-
NMR (300 MHz, DMSO d6, d en ppm): 4.82 (s); 8.12 (t,
J5 8 Hz); 8.27 (t, J5 8 Hz); from 8.45 to 8.65 (mt); 9.68 (s);
10.14 (s); 11.93 (bs; as shown in Scheme 1). In vitro, 360A
and 360B exhibit exactly the same properties for either their
ability to stabilize DNA G-quadruplex structures, such as
telomeric 22AG, or to inhibit cell growth of tumor cells, such
as lung adenocarcinoma cell lines H460 and A549. However,
360B is more soluble in aqueous media (27.6 mg/mL instead
of 0.35 mg/mL for 360A in phosphate buffer at pH 7.4).
For grafting, cells in the active growth phase were washed
and collected in serum-free media. Two microliters
containing 100,000 cells was injected (0.5 mL/min) bilaterally
at the following coordinates (from bregma): AP510.5,
L561.5, and DV523. One week after engraftment, 2 lL
of 10 mM 360B or 2 ml of DMSO diluted in DMEM/F12
medium were microinjected close to the initial position at
3 mm under the dural surface with the incisor bar at 5 mm
above the interaural line.
Immunostaining of brain sections
Animals were deeply anesthetized in a CO2 chamber and
transcardially perfused with a 4% paraformaldehyde solution
in 0.1 M sodium phosphate, pH 7.2. Brains were removed,
postﬁxed for 2 hr in the same solution, cryoprotected with
increasing 10–30% PBS-sucrose solutions, and frozen in dry
ice-cooled isopentane. Serial coronal cryostat sections (30
mm) were processed for hematoxylin and eosin staining or
immunoﬂuorescence. For immunoﬂuorescence, brain sections
were permeabilized with PBS containing 0.3% Triton X-100
and 1% BSA at room temperature for 1 hr and incubated
overnight at 4C with primary antibodies raised against
cleaved-caspase 3 (mAb9579, 1:200; Cell Signaling), human
Nestin (MAB1259, 1:200; R&D systems), or laminin (L939,
1:200; Sigma). After three washes, sections were incubated for
2 hr at room temperature with secondary antibodies coupled
to ﬂuorochromes (FITC or cyanine-3; 1:200; Life Technolo-
gies), rinsed, and mounted with DAPI Fluoromount-G
(Southern Biotech). Mosaic images were captured using a
motorized microscope (Pathﬁnder, Imstar S.A., France)
equipped with a Hamamatsu C8484-05G camera (Hama-
matsu Photonics, France) with the NIS Elements software
v3.1 (Nikon Instruments). Tumor volumes and cell counts
were calculated by multiplying the tumor area or the number
of cells by the distance between successive sections. Confocal
images were captured using the Leica DM 2500 microscope.
Results
TG20 cells exhibit a high level of telomeric recombination
The ALT-mediated elongation of telomeres has been associ-
ated with abundant recombination events between telomeres
of sister chromatids, commonly referred to as telomeric sister
chromatid exchanges (T-SCEs), which are rare or absent in
non-ALT cells.24 As shown by CO-FISH, TG20 cells exhib-
ited a higher rate of T-SCE than the telomerase-positive GSC
line TG16 and the ALT osteosarcoma cell line SAOS-2
Sch 1. Synthesis of “360B.”
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Figure 1. TG20 cells exhibit a high level of telomeric recombination. (a) The chromosome oriented (CO)-FISH procedure was used for T-SCE
analysis. Successive hybridizations with FITC or Cy3-labeled PNA probes allowed detection of the parental telomere C and G strands,
respectively. Telomere lagging strands are stained in red, telomeric leading strands are stained in green, and yellow-stained telomeres are
scored as T-SCEs. The representative metaphase image on the right is an example from the TG20 ALT cell line. The inset shows a chromo-
some with extremities with or without T-SCE. (b) T-SCE results of the depicted cell lines. Values are presented as T-SCE events per 100
chromosome extremities, and “n” indicates the number of chromosome extremities counted (***p<0.001, Student’s t-test). (c) 2D gel elec-
trophoresis and analysis of telomeric DNA after hybridization with a telomeric C-rich probe in TG1N and TG20 GSCs. ds-TRF, double-
stranded telomeric restriction fragments; ss-G, linear single-G-strand telomeric DNA. (d) SCE analysis on TG1N and TG16 telomerase-
positive cell lines and the TG20 ALT cell line. Values are presented as SCE events per 100 chromosomes, and “n” indicates the number of
analyzed chromosomes (ns5 non-significant, p>0.05, Student’s t-test). (e) Representative M-FISH results from late-passage TG20 cells.
Arrows indicate the anomalies.
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(21.4% in TG20 cells vs. 1% in TG16 cells and 9.1% in
SAOS-2 cells, p< 0.001, Figs. 1a and 1b).
Telomeric circles, referred to as t-circles, have been
reported to represent part of the extrachromosomal telomeric
DNA found in ALT cells and could serve as a copy template
for the rolling circle-dependent DNA ampliﬁcation of telo-
mere sequences.25,26 As shown by 2D gel electrophoresis,
TG20 but not TG1N cells exhibited abundant t-circles
(Fig. 1c). Furthermore, signals at the origin of the gel migra-
tion front in the ﬁrst but not the second dimension were also
detected in TG20 cells. As reported previously,27 these signals
correspond to the t-complex, a mixture of highly branched
telomeric DNAs, which are supposed Holliday junction inter-
mediates of telomeric homologous recombination (HR) in
ALT cells.
Contrary to these indicators of a high level of telomere
recombination in TG20 cells, the frequency of exchanges
between SCE was similar in these cells to the frequency
observed in the telomerase-positive GSC lines TG1N and
TG16 (Fig. 1d). Furthermore, karyotypic analysis showed a
single pseudodiploid clone corresponding to 47(XX), del4qter,
17p, 218, 121, t(8;21), t(16;19), t(X;9) in metaphases from
three different passages of TG20 cells (p11, p26, and p30;
Fig. 1e). Other anomalies involving chromosomes #8; 9; 21
and X were detected in some metaphases but did not lead to
the emergence of new clones. Therefore, these cytogenetic
data strongly suggest that TG20 cells have a rather stable
karyotype.
Together, our data show that TG20 cells are characterized
by a high rate of telomere recombination that is not associ-
ated with a high level of chromosome instability.
Methylation is not directly involved in the absence of
hTERT expression in TG20 cells
TG20 cells do not exhibit telomerase activity.6 Consistently,
the transcripts of the catalytic subunit of the human
Figure 2. Absence of hTERT expression in TG20 ALT cells. (a) hTERT mRNA expression in telomerase-positive GSCs (TG16, TG1N, OB1 and TG10)
and ALT cells (TG20 and SAOS-2). Values are presented as the mean6SEM of two independent experiments performed in duplicate. (b) The
same cell lines as in (a) were evaluated but for hTERC mRNA expression. (c) Representative methylation-specific PCR (MSP) results for the proxi-
mal region and WT1 binding site of the TERT promoter in SAOS-2 and TG20 ALT cells and in TG1N and TG16 telomerase-positive cells. Bands in
the M and U lanes represent methylated and unmethylated PCR products, respectively. (d) mRNA expression of hTERT, TES, and RUNX3 in TG20
cells after treatment with 2.5 or 5 mM 5-azacytidine (5-aza), relative to their expression in control DMSO-treated cells. (e) WT1 protein levels
determined by Western blot analysis for the indicated cell lines. b-Actin was used as a loading control. (f) Comparison of expression ratios of
WT1 protein vs. b-actin in the different cell lines. Experiment was repeated twice using samples from independent cell cultures.
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telomerase hTERT were not detected by qRT-PCR in TG20
cells, which was similar to the ﬁndings in SAOS-2 cells (Fig.
2a). In contrast, transcripts of the RNA subunit hTERC were
detected in both ALT cell lines (Fig. 2b), indicating that the
absence of telomerase activity in TG20 cells was related to
the absence of hTERT expression but not to the expression
of hTERC. Importantly, karyotyping demonstrated that TG20
cells possessed two stable copies of the distal portion of chro-
mosome arm 5p, the location of the htert gene (Fig. 1e).
The htert promoter contains clusters of CpG islands where
methylation can occur, suggesting that promoter methylation
might be a key regulator of htert expression.28 Consistently,
two studies have previously shown that htert core promoter
methylation inhibits its expression.29,30 To assess whether
methylation was involved in htert silencing in ALT cells, we
determined the methylation status of a proximal region of
the htert promoter using a MSP-based assay in TG20 cells,
SAOS-2 cells, and the telomerase-positive TG16 and TG1N
cells. In accordance with the role of the methylation of this
region in htert expression regulation, this region was methyl-
ated in the telomerase-negative SAOS-2 cells and unmethy-
lated in the telomerase-positive GSCs (Fig. 2c). However, this
region was also unmethylated in TG20 cells, indicating that
the absence of hTERT expression in an ALT GSC line was
not directly related to the methylation status of the htert
proximal core promoter.
To determine whether the methylation of other regions in
this promoter is involved in the repression of htert, we tested
the effects of 5-azacytidine (5-aza), a chemical analogue of
the cytosine nucleoside that causes global DNA demethyla-
tion, on htert expression. To verify that 5-aza was capable of
demethylating DNA in TG20 cells, we also measured the
expression of two genes known to be downregulated by
hypermethylation in glioblastoma, TES and RUNX3.31 As
shown in Figure 2d, the expression levels of both TES and
RUNX3 but not hTERT were signiﬁcantly increased in TG20
cells following 5-aza treatment. These results conﬁrm that the
absence of telomerase activity in TG20 cells is not directly
related to htert promoter methylation.
Methylation has been shown to prevent the binding of
WT1, a known htert repressor, to a distal region of the htert
promoter in promyelocytic leukemia cells, thereby favoring
hTERT expression.32,33 Because all our telomerase-positive
and ALT cell lines expressed WT1 (Fig. 2e), we investigated
the methylation of one distal promoter region encompassing
the WT1 binding site using MSP, as described above. The
results showed that this region of the promoter was half
methylated in telomerase-positive GSCs, whereas it was com-
pletely unmethylated in TG20 cells. These results support the
previous observation that the methylation of the distal region
of the htert promoter can prevent WT1 binding and thereby
favor hTERT expression (Fig. 2c). These ﬁndings raise the
possibility that the binding of WT1 to this region plays a
role in the repression of htert in the TG20 ALT cell line.
However, the WT1-binding domain of the htert promoter
was fully methylated in SAOS-2 ALT and telomerase-positive
cells, thereby preventing the potential binding of WT1 and
excluding a putative WT1-mediated htert repression as a
mechanism common to all ALT cells.
TG20 cells display a stable ALT phenotype after serial
intracranial transplantations into NOD-SCID-IL2Rc (NSG)
mice
We have previously shown that TG20 cells can generate
intracranial tumors in non-obese diabetic severe combined
immunodeﬁcient NOD-SCID-IL2Rg (NSG) mice.6 To further
characterize the GSC potential of TG20 cells and the stability
of their ALT phenotype, we investigated whether TG20 cells
could sustain tumor formation upon sequential transplanta-
tion into the brain of NSG mice. Thus, TG20 cells and the
telomerase-positive GSC line TG1N were engineered by lenti-
viral infection to stably express eGFP (TG20-eGFP and
TG1N-eGFP cells, respectively). Three months after the ﬁrst
engraftment, the tumor (eGFP-positive) cells were sorted by
FACS (Figs. 3a–3c) and re-injected into the brains of tumor-
naive mice (Fig. 3a). This experiment was successfully
repeated for 2 consecutive transplantations, with a 2-month
interval, further demonstrating that TG20 cells possess the
main characteristics of GSCs (Fig. 3a). After each transplan-
tation, we veriﬁed that sorted eGFP1 cells maintained the
capacity to generate neurospheres in vitro, another character-
istic of stemness (Fig. 3d). Importantly, using the TRAPeze
ELISA assay, we also demonstrated that the sorted cells from
TG1N tumors remained telomerase positive (Fig. 3e) and
that cells from TG20 tumors retained the ALT phenotype
and remained telomerase negative (Fig. 3e). These data indi-
cate that TG20 cells have a stable ALT phenotype, which
allows them to sustain a high number of divisions in vivo as
well as the global self-renewal of GSCs in tumors.
TG20 cells are sensitive to the G-quadruplex ligand 360B
in vivo
As the ﬁrst preclinical model of ALT glioma using human
cells, TG20 tumors generated in mice could be used as a pre-
clinical model to test the efﬁciency of different therapies spe-
ciﬁc to this type of tumor, particularly that of therapies
targeting telomere maintenance mechanisms. G-quadruplex
(G4) ligands have been shown to be promising new com-
pounds in cancer therapy.12–17 We tested the effects of the
G-quadruplex ligand 360B, a close derivative of 360A, that
has been shown to destabilize telomeres and to induce cell
death in cancer cell lines in vitro, including the death of ALT
cell lines.17,19 360B was used instead of 360A, because of its
improved solubility in aqueous media. As shown in Figure
4a, 360B decreased TG20 cell viability in vitro after 7 days of
treatment (Fig. 4a).
To test the effects of 360B on the ALT GSCs in vivo,
100,000 TG20 cells were bilaterally injected into the striatum
of the brain in three NSG mice. One week later, 2 mL of
360B (10 mM) or 2 mL of DMSO (0.1%, vehicle) were
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Figure 3. Stable ALT phenotype in TG20 cells upon serial transplantation. (a) Serial intracranial transplantations of TG20-eGFP cells were performed
in immunodeficient mice. Two or three months after each graft, the brain was removed and sliced coronally. (b and c) Grafted eGFP1 tumors were
microdissected using a Zeiss Lumar V12 fluorescence stereomicroscope. After disaggregation from tissue chunks, TG20-eGFP tumor cells were
sorted by FACS, excluding autofluorescence of non-eGFP cells and dead cells by PI. Appropriate gates were determined using negative (TG20) and
positive (TG20-eGFP) controls from in vitro cultures. Immediately after sorting, 100,000 cells were re-grafted. (d) After dissection and selection, non-
injected eGFP1 cells were cultured to check the formation of eGFP1 neurospheres (scale bar5100 mm). (e) After seven days in culture, telomerase
activity was measured in the formed neurospheres, using the TRAP assay; 500 or 1000 ng of total protein extracts from the first and the second
transplantations (TG20-TS1 and TG20-TS2, respectively) was used. Similar experiments were performed with the telomerase1 TG1N cells grafted
in parallel mice (TG1N-TS1). For each condition, negative controls were performed by heating samples for 10 min at 95C.
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Figure 4. TG20 cells are sensitive to the G-quadruplex ligand 360B in vitro and in vivo. (a) WST-1 proliferation assay for TG20 cells, 7 days
after treatment with the G-quadruplex ligand 360B at different concentrations. Values were calculated relative to the WST-1 absorbance
value of the control cells treated with DMSO. Error bars represent the SEM from four replicates (***p<0.001, Student’s t-test). (b) For
360B testing in vivo, 100,000 TG20 cells were bilaterally injected intracranially into NOD-SCID mouse brains. One week later, DMSO or
360B (2 mL at 10 mM) was injected in the tumor cell injection site. Mice were sacrificed one week after treatment. (c) Representative images
of successive equidistant sections from a brain injected with TG20 cells and treated with either DMSO or 360B, as in b. Panels on the right
and left sides show a magnified image of the TG20 tumor, stained with human Nestin (hNestin; scale bar5100 mm). The lower graph rep-
resents the mean of DMSO- or 360B-treated tumor volumes from n53 animals (*p<0.05, unpaired Student’s t-test).
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injected at the site of tumor cell implantation. The animals
were sacriﬁced after either 7 days (Fig. 4b) or one month
(Fig. 5a). Variants of this drug delivery method have been
previously used for the delivery of neurodegenerative chemi-
cal agents.34,35 Immunostaining for the human nestin protein
was used to detect TG20 cells on serial brain sections and
revealed a signiﬁcant 42% reduction of the mean volume
occupied by the tumor cells in the hemispheres treated with
360B compared with the hemispheres treated with vehicle in
mice sacriﬁced 7 days after treatment (0.0396 0.009 and
0.0926 0.015 mm3 for 360B and vehicle-treated hemispheres,
respectively; n53, unpaired Student’s t-test, p value5 0.036;
Fig. 4c).
The effects of the compound were still detectable one
month after treatment, as shown in two NSG mice by the
40% reduction in human nestin-positive cells in hemispheres
treated with 360B compared with vehicle-treated hemispheres
(p value5 0.0397, unpaired Student’s t-test; Fig. 5b). Addi-
tionally, immunostaining for cleaved caspase-3 showed that
the majority of TG20 cells were undergoing apoptosis in
360B-treated tumors, whereas only rare apoptotic cells were
detected in controls (Fig. 5c). Notably, cleaved caspase-3
expression was detected only in human Nestin-positive cells,
showing that 360B induced glioma cell apoptosis and spared
normal cells. Together these data show the in vivo sensitivity
of TG20 cells to the G-quadruplex ligand 360B, emphasizing
the potential use of G-quadruplex ligands in ALT glioma
therapy and TG20 cells in developing speciﬁc therapeutic
approaches for ALT gliomas.
TG20 cells generate intracranial tumors in nude mice
The use of isolator-reared NSG mice is not trivial, and the
development of different types of experiments is therefore
difﬁcult. We thus assessed the tumorigenicity of TG20 cells
in three nude mice (athymic, T- and B-cell deﬁcient), which
are less permissive to tumor engraftment because they retain
innate immune cells, such as natural killer (NK) cells, but are
easier to manipulate than NSG mice.36 As shown in Figure 6,
TG20 cells generated tumors in nude mice. Immunostaining
of brain sections for human nestin and for laminin, to reveal
TG20 cells and blood vessels, respectively, revealed strong
tumor vascularization 4 months after engraftment (Fig. 6a).
Hematoxylin and eosin staining at 6 months after engraft-
ment also showed microvascular hyperplasia (Fig. 6b).
Discussion
Patients suffering from ALT glioblastomas survive slightly
longer than patients suffering from telomerase-positive glio-
blastomas. The prognosis remains nevertheless dismal, and
the development of speciﬁc new therapies is needed.37,38
Here, we further characterized the ALT phenotype and the
GSC potential of TG20 cells and showed that intracranial
grafts of TG20 cells in NSG and nude mice constituted efﬁ-
cient preclinical models of ALT gliomas, which could aid the
understanding of ALT glioma pathogenesis and the develop-
ment of speciﬁc therapies.
ALT cells replicate their telomeres in a recombination-
dependent manner.3 Consistently, we found that TG20 cells
exhibited a high rate of telomeric recombination, as revealed
by high levels of T-SCEs, T-circles, and T complexes, all of
which have been associated with the ALT mechanism.24–26
This high level of recombination concerns only telomeres
because the frequencies of SCE elsewhere in the genome are
similar in TG20 cells and telomerase-positive GSCs, suggest-
ing that the dysregulation of recombination is not global in
TG20 cells but is likely telomere speciﬁc, which could be a
general feature of ALT cells as previously proposed by
Bechter et al.39
TG20 cells, similarly to other ALT cells, form numerous
telomere dysfunction-induced foci (TIF), a telomere-speciﬁc
DNA damage response analogous to a double-strand break
Figure 5. Long-term in vivo efficiency of the G-quadruplex ligand
360B on TG20 cells. (a) TG20 cells were injected intracranially into
each hemisphere of NOD-SCID mouse brains, and drugs were
added one week later, as in Figure 4b. Mice were sacrificed one
month after treatment. (b) The percentage of tumor reduction in
360B-treated versus DMSO-treated hemispheres was evaluated by
counting the remaining TG20 cells in each brain section (*p<0.05,
Student’s t-test). (c and d) Immunofluorescence in representative
brain sections shows human Nestin (hNestin) staining and cleaved
caspase-3 or laminin staining. n52 animals (scale bar540 mm).
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Figure 6. TG20 cells generate tumors in nude mice. (a) Immunofluorescence staining in a nude mouse brain slice containing a TG20 tumor
4 months after cell engraftment. The right panels show separate immunostaining of hNestin, laminin, and DAPI, and the left panel shows
an enlarged merge image of these immunostained sections (scale bar50.3 mm). The inset shows high vascularization of the tumor (scale
bar50.15 mm). (b) Representative hematoxylin & eosin staining of TG20 tumors 6 months after engraftment in nude mice shows large
blood vessels (indicated by arrows), specifically in the tumor region. Representative image of n53 animals (scale bar51 mm).
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response, which indicates that telomeres are deprotected.6,40
The main function of telomeres is to protect chromosomes
from end-to-end fusions. The relative stability of the TG20 cell
karyotype suggests that despite abundant signals of dysfunction
and a high rate of recombination, the telomeres of TG20 cells
retain their protective function against chromosome instability.
The shelterin complex plays an essential role in telomere cap-
ping, which protects the chromosome ends from being recog-
nized as DNA damage sites and/or from fusions.41 Cesare
et al.40 have proposed that the telomeres of ALT cells have an
intermediate state of telomere capping, where telomeres are less
saturated with shelterin proteins. Such capping is supposedly
efﬁcient enough to inhibit end-to-end telomere fusions, but it
induces a DNA-damage response and subsequent telomeric
recombination, as observed here in TG20 cells.
The potential interest of developing speciﬁc anticancer
strategies against ALT mechanisms is largely dependent on
the stability of the ALT phenotype. Furthermore, determining
the mechanisms by which telomerase is repressed in ALT
cells may provide a better understanding of the pathogenetic
mechanisms that lead to the emergence of this type of cancer
cell. We have shown that the ALT phenotype of TG20 cells
is stable upon serial transplantation in mice and that TG20
cells do not reacquire telomerase activity after several trans-
plantations in vivo. As for the majority of ALT cells, the
absence of telomerase activity in TG20 cells is directly related
to the lack of expression of the catalytic subunit hTERT. One
proposed mechanism of tert gene repression in ALT cells is
DNA methylation of the tert promoter, as global DNA-
demethylating compounds have been shown to induce the
expression of TERT mRNA in some ALT cells, such as
SUSM-1, U2OS, and GM847 cells.42,43 Unlike those cells, tert
gene repression in TG20 cells does not appear to be related
to promoter methylation. Demethylation treatment did not
stimulate TERT expression in TG20 cells, indicating that
other stable mechanisms of repression are involved. One of
these mechanisms could be mediated by WT1, a transcrip-
tional repressor of hTERT. In TG20 cells, we showed that the
WT1 binding site, which is present in the distal region of the
tert promoter, was unmethylated, a condition required for
WT1 repression of htert transcription.32,33
Serial transplantations of TG20 cells into NOD-SCID
mice showed that GSCs did not absolutely require telomerase
activation to maintain their telomeres in a selective in vivo
environment and conﬁrmed that the ALT pathway is capable
of supporting the long-term proliferative potential and self-
renewal capacity of these cells. GSCs are supposed to play an
essential role in glioma relapse because of their putative
resistance to current treatments and their capacity to regener-
ate tumors.8 As a GSC line, TG20 cells can be used to screen
potential anticancer compounds during the initial phase of
tumor generation in mice in the hopes of evaluating their
effects more precisely on GSCs rather than on
“differentiated” cancer cells. Because ALT-speciﬁc therapies
have not yet been identiﬁed, we decided to test the G-
quadruplex ligand 360B on TG20 cells. Given the importance
of G-quadruplexes in telomere homeostasis, ligands stabiliz-
ing these structures have been developed for use as antitumor
therapeutic strategies.12–17 360A, a pyridine derivative, has
been shown to target G4 telomeric structures and to impair
telomere replication and mitotic progression leading to cell
death.17–19,21 While G-quadruplex ligands have been exten-
sively tested in telomerase-positive cells, to our knowledge,
no data exist on the effects of these ligands on ALT tumors
in vivo. 360A has been previously shown to efﬁciently reduce
the proliferation of telomerase-positive glioma cell lines and
SAOS-2 cells in vitro.17 We showed here that TG20 cells
were sensitive both in vitro and in vivo to 360B, demonstrat-
ing that this treatment impairs tumor development when
performed at the initiation phase just after engraftment.
These encouraging results emphasize the potential interest
of targeting G-quadruplex structures for ALT glioma treat-
ments. However, the effects of 360B on established tumors
and its potential use in combination with other treatments
such as ionizing radiation and the alkylating agent temozolo-
mide, which is currently used in glioblastoma patients after
surgery, should be now investigated.44 Accordingly, intracere-
bral grafts of TG20 cells in nude mice could be of great inter-
est because contrary to NSG mice, nude mice are not
particularly radiosensitive.
To conclude, we have conﬁrmed and further characterized
the ALT phenotype and GSC potential of TG20 cells, and
our ﬁndings indicate that intracerebral TG20 grafts in immu-
nodeﬁcient mice represent an attractive preclinical model of
ALT glioma. TG20 cells have been isolated from a second-
relapse glioblastoma in a 38-year-old patient that beneﬁted
from the STUPP protocols.6 This model could therefore be
particularly adapted to evaluate the effects of treatment on
resistant tumors.
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